Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
McKesson
Harvard Business School

Last Updated: September 25, 2022

QNASL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Qnasl, and what generic alternatives are available?

Qnasl is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-two patent family members in thirty-two countries.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch® Generic Entry Outlook for Qnasl

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 24, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for QNASL
Drug patent expirations by year for QNASL
Drug Prices for QNASL

See drug prices for QNASL

DrugPatentWatch® Estimated Generic Entry Opportunity Date for QNASL
Generic Entry Date for QNASL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
AEROSOL, METERED;NASAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for QNASL

US Patents and Regulatory Information for QNASL

QNASL is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of QNASL is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting QNASL

Nasal spray device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dispensing apparatus with dosage counter
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-002 Dec 17, 2014 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-002 Dec 17, 2014 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for QNASL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-002 Dec 17, 2014 See Plans and Pricing See Plans and Pricing
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012 See Plans and Pricing See Plans and Pricing
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012 See Plans and Pricing See Plans and Pricing
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for QNASL

When does loss-of-exclusivity occur for QNASL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Patent: 7763
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 58631
Estimated Expiration: See Plans and Pricing

Germany

Patent: 2005019404
Estimated Expiration: See Plans and Pricing

Spain

Patent: 39574
Estimated Expiration: See Plans and Pricing

United Kingdom

Patent: 11384
Estimated Expiration: See Plans and Pricing

Patent: 14187
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QNASL around the world.

Country Patent Number Title Estimated Expiration
Denmark 595789 See Plans and Pricing
Croatia P20190337 See Plans and Pricing
Hungary E043276 See Plans and Pricing
Germany 68904300 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Express Scripts
AstraZeneca
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.